Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sonoma Pharmaceuticals stock

Own Sonoma Pharmaceuticals stock in just a few minutes.

Sonoma Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Sonoma Pharmaceuticals shares (SNOA) are listed on the NASDAQ and all prices are listed in US Dollars. Sonoma Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Sonoma Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SNOA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sonoma Pharmaceuticals share price

Use our graph to track the performance of SNOA stocks over time.

Sonoma Pharmaceuticals shares at a glance

Information last updated 2021-04-23.
52-week range$4.60 - $10.09
50-day moving average $7.74
200-day moving average $7.89
Wall St. target price$9.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.06

Buy Sonoma Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sonoma Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sonoma Pharmaceuticals financials

Revenue TTM $21.8 million
Gross profit TTM $8.3 million
Return on assets TTM -11.3%
Return on equity TTM -19.6%
Profit margin -7.64%
Book value $5.92
Market capitalisation $16.5 million

TTM: trailing 12 months

Shorting Sonoma Pharmaceuticals shares

There are currently 20,645 Sonoma Pharmaceuticals shares held short by investors – that's known as Sonoma Pharmaceuticals's "short interest". This figure is 1749.9% up from 1,116 last month.

There are a few different ways that this level of interest in shorting Sonoma Pharmaceuticals shares can be evaluated.

Sonoma Pharmaceuticals's "short interest ratio" (SIR)

Sonoma Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Sonoma Pharmaceuticals shares currently shorted divided by the average quantity of Sonoma Pharmaceuticals shares traded daily (recently around 42132.653061224). Sonoma Pharmaceuticals's SIR currently stands at 0.49. In other words for every 100,000 Sonoma Pharmaceuticals shares traded daily on the market, roughly 490 shares are currently held short.

However Sonoma Pharmaceuticals's short interest can also be evaluated against the total number of Sonoma Pharmaceuticals shares, or, against the total number of tradable Sonoma Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sonoma Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Sonoma Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.01% of the tradable shares (for every 100,000 tradable Sonoma Pharmaceuticals shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sonoma Pharmaceuticals.

Find out more about how you can short Sonoma Pharmaceuticals stock.

Sonoma Pharmaceuticals share dividends

We're not expecting Sonoma Pharmaceuticals to pay a dividend over the next 12 months.

Have Sonoma Pharmaceuticals's shares ever split?

Sonoma Pharmaceuticals's shares were split on a 1:9 basis on 19 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonoma Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Sonoma Pharmaceuticals shares which in turn could have impacted Sonoma Pharmaceuticals's share price.

Sonoma Pharmaceuticals share price volatility

Over the last 12 months, Sonoma Pharmaceuticals's shares have ranged in value from as little as $4.6 up to $10.09. A popular way to gauge a stock's volatility is its "beta".

SNOA.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonoma Pharmaceuticals's is 0.7976. This would suggest that Sonoma Pharmaceuticals's shares are less volatile than average (for this exchange).

Sonoma Pharmaceuticals overview

Sonoma Pharmaceuticals, Inc. , develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Sonoma Pharmaceuticals is owned by insiders or institutions?
Currently 1.066% of Sonoma Pharmaceuticals shares are held by insiders and 8.902% by institutions.
How many people work for Sonoma Pharmaceuticals?
Latest data suggests 19 work at Sonoma Pharmaceuticals.
When does the fiscal year end for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals's fiscal year ends in March.
Where is Sonoma Pharmaceuticals based?
Sonoma Pharmaceuticals's address is: 645 Molly Lane, Woodstock, GA, United States, 30102
What is Sonoma Pharmaceuticals's ISIN number?
Sonoma Pharmaceuticals's international securities identification number is: US83558L2043
What is Sonoma Pharmaceuticals's CUSIP number?
Sonoma Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 67575P108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site